Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12C
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
Guardant360® CDx (54)
therascreen® KRAS RGQ PCR Kit (5)
Resolution ctDx FIRST Assay (1)
Guardant360® CDx (54)
therascreen® KRAS RGQ PCR Kit (5)
Resolution ctDx FIRST Assay (1)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
panitumumab + sotorasib
Sensitive: B - Late Trials
ESMO Asia 2023 - 6 days (New B)
panitumumab + sotorasib
Sensitive
:
B
ESMO Asia 2023 - 6d
panitumumab + sotorasib
Sensitive: B - Late Trials
ESMO Asia 2023 - 6 days
panitumumab + sotorasib
Sensitive
:
B
ESMO Asia 2023 - 6 days - (New B)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
adagrasib
Sensitive: A1 - Approval
Mirati Therapeutics Press Release - 3 weeks (New C3)
adagrasib
Sensitive
:
A1
Mirati Therapeutics Press Release - 3wk
adagrasib
Sensitive: A1 - Approval
Mirati Therapeutics Press Release - 3 weeks
adagrasib
Sensitive
:
A1
Mirati Therapeutics Press Release - 3 weeks - (New C3)
KRAS G12C
Multiple Myeloma
KRAS G12C
Multiple Myeloma
MRTX1257
Sensitive: D – Preclinical
ASH 2023 - 4 weeks (New D)
MRTX1257
Sensitive
:
D
ASH 2023 - 4wk
MRTX1257
Sensitive: D – Preclinical
ASH 2023 - 4 weeks
MRTX1257
Sensitive
:
D
ASH 2023 - 4 weeks - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
RMC-4550 + RM-029
Sensitive: D – Preclinical
SITC 2023 - 4 weeks (New D)
RMC-4550 + RM-029
Sensitive
:
D
SITC 2023 - 4wk
RMC-4550 + RM-029
Sensitive: D – Preclinical
SITC 2023 - 4 weeks
RMC-4550 + RM-029
Sensitive
:
D
SITC 2023 - 4 weeks - (New D)
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
KRAS G12C
Colon Cancer
KRAS G12C
Colon Cancer
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
cetuximab + adagrasib
Sensitive: B - Late Trials
cetuximab + adagrasib
Sensitive
:
B
cetuximab + adagrasib
Sensitive: B - Late Trials
cetuximab + adagrasib
Sensitive
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
panitumumab
Resistant: B - Late Trials
panitumumab
Resistant
:
B
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib + BMS-986466
Sensitive: B - Late Trials
sotorasib + BMS-986466
Sensitive
:
B
sotorasib + BMS-986466
Sensitive: B - Late Trials
sotorasib + BMS-986466
Sensitive
:
B
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
JAB-21822
Sensitive: B - Late Trials
JAB-21822
Sensitive
:
B
JAB-21822
Sensitive: B - Late Trials
JAB-21822
Sensitive
:
B
KRAS G12C
Ampulla of Vater Carcinoma
KRAS G12C
Ampulla of Vater Carcinoma
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Cholangiocarcinoma
KRAS G12C
Cholangiocarcinoma
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Ovarian Cancer
KRAS G12C
Ovarian Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Pancreatic Cancer
KRAS G12C
Pancreatic Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Endometrial Cancer
KRAS G12C
Endometrial Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
KRAS G12C
Melanoma
KRAS G12C
Melanoma
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Endometrial Cancer
KRAS G12C
Endometrial Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Gastrointestinal Cancer
KRAS G12C
Gastrointestinal Cancer
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
sotorasib
Sensitive: C1 - Off-label
sotorasib
Sensitive
:
C1
KRAS G12C
Gastrointestinal Cancer
KRAS G12C
Gastrointestinal Cancer
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
adagrasib
Sensitive: C1 - Off-label
adagrasib
Sensitive
:
C1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login